<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930679</url>
  </required_header>
  <id_info>
    <org_study_id>TNLS/2018-03</org_study_id>
    <nct_id>NCT04930679</nct_id>
  </id_info>
  <brief_title>Evaluating Safety of Andiabet on Diabetes Mellitus Type II Patients, Phase I CT.</brief_title>
  <official_title>A Phase I, Open-label Safety Evaluation of Andiabet of Traphaco J.S.C on Diabetes Mellitus Type II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre of Clinical Pharmacology, Hanoi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Clinical Pharmacology, Hanoi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I clinical trial is used to evaluate the safety of Andiabet, a herbal-derived&#xD;
      medicinal product that assists in the treatment of type 2 Diabetes (T2D). Thereby, determine&#xD;
      efficacy of the drug on stabilizing blood glucose in T2D patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 28-day phase I, open-label clinical trial to evaluate safety of Andiabet on . The&#xD;
      general purpose is the evaluate safety via adverse events and tolerability of Andiabet on T2D&#xD;
      patients, and evaluate effect of Andiabet on clinical and laboratory parameters.&#xD;
&#xD;
      The study conducted on volunteering T2D patients, whose HbA1c level is =&lt; 7.5% and are not&#xD;
      pregnant, had no records of addiction, allergy, hypersensitivity, and chronic diseases. The&#xD;
      main evaluation criteria are fasting glucose, used for evaluating efficacy and safety, which&#xD;
      evaluated based on adverse events.&#xD;
&#xD;
      Ensuring quality of the data:&#xD;
&#xD;
      Sponsor and CRO are supervisors. Supervision will be conducted periodically, ensuring the&#xD;
      compliance with the research proposal, following GCP.&#xD;
&#xD;
      Hanoi Medical University-Clinical center of Pharmacology is responsible for managing the&#xD;
      data. Completed CFR are sent to the Center of Clinical Pharmacology, entered by Microsoft&#xD;
      Excel and analysed using SPSS 16.0 Before analysing, these data will be checked randomly,&#xD;
      avoiding errors in data entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2018</start_date>
  <completion_date type="Actual">February 22, 2019</completion_date>
  <primary_completion_date type="Actual">February 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 diabetes type 2 patients are recruited, in which 14 took part in the study, randomly divided into 2 arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>2 AEs recorded, there were changes in biochemical indices. However, these AEs are considered mild and unrelated to the investigated product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>28 days</time_frame>
    <description>Group II is reported to have lower blood glucose compared to group I. However, the difference is efficacy is not clear between 2 groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andiabet</intervention_name>
    <description>Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participants must meet ALL the following criteria:&#xD;
&#xD;
          -  Type 2 Diabetes (T2D) patients with HbA1c lower than or equal to 7.5%&#xD;
&#xD;
          -  BMI range: 18-40 kg/m2&#xD;
&#xD;
          -  Diagnosed with T2D or currently treating T2D (prescribed by physicians) with one or&#xD;
             more of the following drugs: Metformin, Sulfonyl urea, dipeptidyl peptidase-4&#xD;
             inhibitors, or a-glucosidase inhibitors&#xD;
&#xD;
          -  Be able to stop using T2D drugs in 4 weeks, while maintaining diets and exercising&#xD;
             routine.&#xD;
&#xD;
          -  Willing to take part in the study.&#xD;
&#xD;
        Exclusion Criteria: Participants that have ONE of the following:&#xD;
&#xD;
          -  Diagnosed with Type 1 Diabetes.&#xD;
&#xD;
          -  History of complications due to Diabetes Mellitus.&#xD;
&#xD;
          -  History of cardiovascular diseases: hypertension, heart failure, Unstable agina,&#xD;
             stroke or transient ischemic attack, myocardial infarction, arrhythmias, coronary&#xD;
             artery interventions.&#xD;
&#xD;
          -  History of drugs, alcohol addiction.&#xD;
&#xD;
          -  Uncontrolled high blood pressure&#xD;
&#xD;
          -  Pre-study screening blood test with abnormal results in total blood compositions,&#xD;
             urea, AST, ALT, creatinine, albumin, total bilirubin, total urine analysis.&#xD;
&#xD;
          -  Test positive for HIV or HbsAg&#xD;
&#xD;
          -  Abnormal ECG results that are clinically significant.&#xD;
&#xD;
          -  History of hypersensitivity to any of the ingredients in the testing product.&#xD;
&#xD;
          -  Female participants that are pregnant or having pregnancy intention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung C Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Clinical Pharmacology, Hanoi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Clinical Pharmacology, Hanoi Medical University</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

